MoonLake Immunotherapeutics (MLTX) Competitors $46.36 -1.50 (-3.12%) As of 07/3/2025 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, and ELANShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Ascendis Pharma A/S (NASDAQ:ASND) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate ASND or MLTX? Ascendis Pharma A/S presently has a consensus target price of $220.67, suggesting a potential upside of 26.77%. MoonLake Immunotherapeutics has a consensus target price of $74.50, suggesting a potential upside of 60.68%. Given MoonLake Immunotherapeutics' higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, ASND or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M27.04-$409.12M-$6.28-27.72MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.16 Which has more volatility and risk, ASND or MLTX? Ascendis Pharma A/S has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Do institutionals & insiders believe in ASND or MLTX? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ASND or MLTX? In the previous week, Ascendis Pharma A/S had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 2 mentions for MoonLake Immunotherapeutics. Ascendis Pharma A/S's average media sentiment score of 0.99 beat MoonLake Immunotherapeutics' score of 0.59 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ASND or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -93.22%. Ascendis Pharma A/S's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-93.22% N/A -33.29% MoonLake Immunotherapeutics N/A -30.81%-28.40% SummaryMoonLake Immunotherapeutics beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06B$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E Ratio-20.1621.5627.4020.24Price / SalesN/A277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book6.547.518.085.67Net Income-$118.94M-$55.05M$3.16B$248.47M7 Day Performance-2.43%4.59%2.81%3.29%1 Month Performance-9.18%4.86%3.69%5.18%1 Year Performance9.87%5.82%35.30%21.35% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics1.9868 of 5 stars$46.37-3.1%$74.50+60.7%+9.9%$3.06BN/A-20.162News CoveragePositive NewsASNDAscendis Pharma A/S3.5573 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017Analyst ForecastVTRSViatris3.2791 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.33B-2.7932,000QGENQiagen4.0702 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3889 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.7454 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6594 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$8.03B$42.28M-48.5330Analyst ForecastBBIOBridgeBio Pharma4.7106 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$7.92B$221.90M-11.95400Insider TradeAnalyst RevisionROIVRoivant Sciences1.9654 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.5734 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.2612 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.68B$4.44B18.059,000Analyst Forecast Related Companies and Tools Related Companies ASND Competitors VTRS Competitors QGEN Competitors MRNA Competitors BPMC Competitors VRNA Competitors BBIO Competitors ROIV Competitors RVMD Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts